Highlighs in MBC: Discussions

TROPiCS-02

ASCO 2022

More data needed: Are the results clinical meaningful?…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

PALOMA-2

ASCO 2022

What are the cosenquences of the new OS data for CDK4/6…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

MAINTAIN

ASCO 2022

CDK4/6i switch: who benefits from switching the CDK4/6…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

Destiny-Breast04

ASCO 2022

Paradigm shift in breast cancer: Where do we use the…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

ASCO 2022

Transatlantic differences in ADC side effects…

Hope Rugo, MD; Diana Lüftner, MD; Volkmar Müller, MD

MBC treatment Perspectives: Discussion

Destiny-Breast04; U31402-A-J101; PALOMA-2; MAINTAIN

ASCO 2022

ADCs & CDK4/6i - paradigm shifts and therapy switches…

J. Cortes, D. Lüftner, P. Fasching

Destiny-Breast04

ASCO 2022

Determining HER2 receptor expression: How do we target…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

Tropics02; Destiny-Breast04

ASCO 2022

Patients perspectives: ADCs - how do manage the new,…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

MAINTAIN

ASCO 2022

How to determine progress of disease? How to proceed…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

TROPiCS-02

ASCO 2022

What clincial value has statistical signifcance? How…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

Breast cancer metastatic: 100 seconds ENG

PALOMA-2; MAINTAIN

ASCO 2022

No changes in clinical practice after new CDK4/6i-data

Alessandra Gennari, MD

TROPiCS-02

ASCO 2022

ADC: future therapeutic option in advanced HR+/HER2 BC

Wolfgang Janni, MD

Destiny-Breast04

ASCO 2022

Gamechanger in breast cancer

Gil Morgan, MD

Destiny-Breast04

ASCO 2022

T-DxD should be the new SoC for Her2low MBC patients

Sara Tolaney, MD

PALOMA-2

ASCO 2022

Possible explanations of the negative study

Andreas Schneeweiss, MD

Tropics02

ASCO 2022

Good therapeutic option in HR+ HER2- mBC after failure…

Andreas Schneeweiss, MD

NeoSTAR

ASCO 2022

Sacituzumab govitecan improves PCr in patients with…

Sara Tolaney, MD

PALOMA-2

ASCO 2022

Disappoiting final OS data and its implications for our…

Diana Lüftner, MD; Volkmar Müller, MD

BioItaLEE

ASCO 2022

Combination of ctDNA and TKa assesment may improve…

Carmen Criscitiello, MD

MAINTAIN

ASCO 2022

Additional administration of ribociclib improves PFS…

Andreas Schneeweiss, MD

coopERA BC

ASCO 2022

Combi SERD + Palbo reduces proliferation better than…

Peter Fasching, MD

Destiny-Breast 04; Tropics-02

ASCO 2022

Impressive and practice changing data of ADCs mark the…

Barbara Pistilli, MD

NRG-BR002

ASCO 2022

No effect for local treatment of metastasis

Andreas Schneeweiss, MD

NRG-BR002

ASCO 2022

Discontiunation of trial is disappointing despite…

Karen Gelmon, MD

Destiny-Breast04

ASCO 2022

New SoC for large subpopulation of breast cancer…

Elzbieta Senkus-Konefka, MD

ASCO 2022

Patritumab Deruxtecan: HER3-targeted ADC in HER3…

Andreas Schneeweiss, MD

FAKTION

ASCO 2022

Improvment of PFS & OS with activated alteration…

Andreas Schneeweiss, MD

DESTINY-Breast04; TROPiCS-02

ASCO 2022

Breakthrough news with antibody drug conjugate

Michael Untch, MD

MAINTAIN

ASCO 2022

First evidence on benefit of CDK4/6 inhibitors beyond…

Elzbieta Senkus-Konefka, MD

NRG-BR002

ASCO 2022

Oligometastasis: no advantage of additional…

Wolfgang Janni, MD

Destiny-Breast04

ASCO 2022

New standard of care for HR+/Her2low patients

Karen Gelmon, MD

PALOMA-2

ASCO 2022

Palbociclib - Overall survival data

Nadia Harbeck, MD

MAINTAIN

ASCO 2022

Benefit of CDK4/6 Switch after Progression

Wolfgang Janni, MD

Destiny-Breast04

ASCO 2022

Exciting and practice changing news for HR+/Her2low MBC…

Carmen Criscitiello, MD

Destiny-Breast04, Destiny-Breast03, TROPiCS-2, PALOMA-2, MAINTAIN, NRG-BR002

ASCO 2022

My ASCO22 highlights in metastatic breast cancer

Fatima Cardoso, MD

FAKTION

ASCO 2022

Option for overcoming endocrine resistance?

Wolfgang Janni, MD

ASTER

ASCO 2022

Endocrine therapy alone is important in treatment of…

Karen Gelmon, MD

Destiny-Breast04

ASCO 2022

Revolution in the field of HR+ disease

Giuseppe Curigliano, MD

Tropics02

ASCO 2022

SG is a new therapy option for HR+/HER2- MBC patients

Carmen Criscitiello, MD

DESTINY-Breast04; TROPiCS-02

ASCO 2022

New agents for the clincial practice

Javier Cortes, MD

TROPiCS-02

ASCO 2022

Smart chemotherapy improves PFS

Giuseppe Curigliano, MD

TROPiCS-02

ASCO 2022

SG may be a good option for pre-treated HR+/Her2- pts

Sara Tolaney, MD

Tropics02; Destiny-Breast04

ASCO 2022

Fascinating data of ADCs in breast cancer at ASCO22

Véronique Diéras, MD

TROPICS-02; Destiny-Breast04

ASCO 2022

Exciting advances across a wide subset of breast…

Hope Rugo, MD

Destiny-Breast04

ASCO 2022

Practice changing data

Nadia Harbeck, MD

Breast Cancer metastatic: 100 seconds Multi Language

BioItaLEE

ASCO 2022

La valutazione combinata di ctDNA e TKa può aiutare a…

Carmen Criscitiello, MD

Destiny-Breast 04; Tropics-02

ASCO 2022

I nuovi impressionanti risultati degli ADC a l’ASCO…

Barbara Pistilli, MD

DESTINY-Breast04; TROPiCS-02

ASCO 2022

ADCs en cáncer de mama con receptores hormonales…

Javier Cortes, MD

Destiny-Breast 04; Tropics-02

ASCO 2022

Les nouvelles données impressionnantes des ADC à l’ASCO…

Barbara Pistilli, MD

Destiny-Breast04

ASCO 2022

Novità entusiasmanti e practice changing per le…

Carmen Criscitiello, MD

Destiny-Breast04

ASCO 2022

Una rivoluzione per il tumore mammario…

Giuseppe Curigliano, MD

Destiny-Breast04, Tropics-02

ASCO22

Noutăți inovatoare cu conjugatul de medicamente cu…

Michael Untch, MD

Destiny-Breast04

ASCO 2022

Nowy standard dla znaczącej subopulacji chorych na raka…

Elzbieta Senkus-Konefka, MD

MAINTAIN

ASCO 2022

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…

Elzbieta Senkus-Konefka, MD

TROPiCS-02

ASCO 2022

Il sacituzumab govitecan migliora il PFS nei tumori…

Giuseppe Curigliano, MD

PALOMA-2; MAINTAIN

ASCO 2022

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Alessandra Gennari, MD

Tropics02

ASCO 2022

SG come nuova opzione di cura per le pazienti con…

Carmen Criscitiello, MD

Early breast Cancer: Discussions

Aster 70s

ASCO 2022

CT benefit for elderly patients, if they are able to…

N. Harbeck, K. Gelmon, C. Criscitiello, A. Schneeweiss, A. Gennari, M. Untch

LUMINA

ASCO 2022

Adding towards deescalation in luminal A EBC by…

N. Harbeck, A. Gennari, K. Gelmon, C. Criscitiello, M. Untch

ABCSG-18

ASCO 2022

Long term overall survival benefit of Denosumab in…

A. Schneeweiss, N. Harbeck, K. Gelmon, C. Criscitiello, A. Schneeweiss, A. Gennari, M. Untch

ASTRRA

ASCO 2022

Ovarian function suppression - it is here to stay!

C. Criscitiello, A. Schneeweiss, A. Gennari, K. Gelmon, M. Untch, N. Harbeck

KEYNOTE-522; NeoSTAR

ASCO 2022

Neoadjuvant Pembro decreased RCB. SG - first promising…

N. Harbeck, C. Criscitiello, K. Gelmon, A. Gennari, M. Untch

Breast cancer early: 100 seconds

ADAPT

ASCO 2022

High concordance of local, central IHC and RT-PCR for…

Nadia Harbeck, MD

coopERA BC

ASCO 2022

Combi SERD + Palbo redzuert proliferation better than…

Peter Fasching, MD

iSPY-2, Keynote-522, ASTER-70s, ASTRRA, ABCSG-18

ASCO 2022

My ASCO22 highlights in early breast cancer

Fatima Cardoso, MD

NSCLC metastatic: Discussion

CheckMate 227; CheckMate 9LA; FDA pooled

ASCO 2022

Immunotherapy - Part 1

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

KRYSTAL-1

ASCO 2022

Molecular landscape - Part 1

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Lung-MAP

ASCO 2022

Immunotherapy - Part 2

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

CHRYSALIS-2; CHRYSALIS

ASCO 2022

Molecular landscape - Part 2

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

NSCLC metastatic: 100 Seconds ENG

ASCO 2022

CLN-081 is a promising new agent for EGFR exon 20…

Stephen, Liu, MD

CHRYSALIS-2; CHRYSALIS

ASCO 2022

New components and therapies for advanced NSCLC

Noemi Reguart, MD

CHRYSALIS

ASCO 2022

New treatment options for METexon 14 skipping:…

Lizza Hendriks, MD

COSMIC-021

ASCO 2022

COSMIC-021: Not practice-changing, but interesting…

Sacha Rothschild, MD

CHRYSALIS

ASCO 2022

New option in patients harboring METex14 mutation

Nicolas Girard, MD

KRYSTAL-1

ASCO 2022

Is adagrasib an alternative to sotorasib?

Riyaz Shah, MD

ASCO 2022

CLN-081 for patients with metastatic NSCLC and an…

Lizza Hendriks, MD

CHRYSALIS

ASCO 2022

Amivantamab as a future option for METex14 patients?

Stephen Liu, MD

FDA pooled analysis

ASCO 2022

PD-L1 over 50%: Chemo-IO or IO?

Riyaz Shah, MD

CHRYSALIS

ASCO 2022

Bispecific Antibodies - the cMET field is moving

Michael Thomas, MD

KRYSTAL-1

ASCO 2022

Promising results for pre-treated patients with…

Lizza Hendriks, MD

CodeBreaK100

ASCO 2022

Multiple aquired resistance mutations may drive disease…

Riyaz Shah, MD

KRYSTAL-1

ASCO 2022

In the second line: Options for Immunotherapy…

Noemi Reguart, MD

FDA pooled analysis

ASCO 2022

Strategies for PD-L1 > 50%

Hossein Borghaei, MD

FDA pooled

ASCO 2022

Role of IO and chemo-IO in patients with PD-L1 > 50%

Sacha Rothschild, MD

KRYSTAL-1

ASCO 2022

KRASG12C mutation: Adagrasib is comparabale to…

Nicolas Girard, MD

CHRYSALIS-2

ASCO 2022

A chemo-free option in patients with EGFR-mutation

Stephen Liu, MD

Lung-MAP; KRYSTAL-1

ASCO 2022

Options after progression to chemo/IO and for KRASG12C…

Hossein Borghaei, MD

NSCLC metastatic: 100 seconds Multi Language

FDA pooled

ASCO 2022

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…

Sacha Rothschild, MD

KRYSTAL-1

ASCO 2022

L’adagrasib, inhibiteur de la mutation KRASG12C: une…

Nicolas Girard, MD

CHRYSALIS

ASCO 2022

Nieuwe behandelopties voor METexon 14 skipping:…

Lizza Hendriks, MD

KRYSTAL-1; Lung-MAP

ASCO 2022

Segunda Linea: opciones tras resistencia a…

Noemi Reguart, MD

ASCO 2022

PD-L1 über 50 % - was tun?

Michael Thomas, MD

COSMIC-021

ASCO 2022

COSMIC-021: Nicht praxisverändernd, aber interessante…

Sacha Rothschild, MD

ASCO 2022

Was tun nach Versagen einer Chemoimmun-Therapie?

Michael Thomas, MD

ASCO 2022

CLN-081 voor patienten met gemetastaseerd NSCLC en een…

Lizza Hendriks, MD

KRYSTAL-1

ASCO 2022

Veelbelovende resultaten voor voorbehandelde patienten…

Lizza Hendriks, MD

ASCO 2022

Bispezifische Antikörper - Neues von CHRYSALIS

Michael Thomas, MD

CHRYSALIS-2; CHRYSALIS

ASCO 2022

Nuevas terapias para el CPCNP avanzado

Noemi Reguart, MD

CHRYSALIS

ASCO 2022

Une nouvelle option, l’amivantamab, en situation de…

Nicolas Girard, MD

NSCLC early stages: Discussion

NADIM II; CheckMate 816

ASCO 2022

Neoadjuvant and adjuvant therapy - Part 2

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

NADIM II; CheckMate 816

ASCO 2022

Neoadjuvant and adjuvant therapy - Part 1

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

NSCLC early stages: 100 seconds

NADIM II

ASCO 2022

Perspectives on multimodality

Michael Thomas, MD

CheckMate-816

ASCO 2022

CheckMate-816: Neoadjuvant therapy

Frank Griesinger, MD

KEYNOTE-799

ASCO 2022

New treatment approaches in Stage III

Martin Reck, MD

NADIM II

ASCO 2022

A new option in neoadjuvant chemoimmunotherapy

Denis Moro-Sibilot, MD

NADIM-II

ASCO 2022

NADIM-II strengthens the findings from CheckMate-816

Gil Morgan, MD

NSCLC early stages: 100 seconds Multi Language

KEYNOTE-799

ASCO 2022

Neue Ansätze im Stadium III

Martin Reck, MD

NADIM II

ASCO 2022

Chimiothérapie néoadjuvante des stades III , vers un…

Denis Moro-Sibilot, MD

SCLC: 100 Seconds ENG

SKYSCRAPER-02

ASCO 2022

SKYSCRAPER-02: Subgroups could be important

Michael Thomas, MD

SKYSCRAPER-02

ASCO 2022

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…

Denis Moro-Sibilot, MD

ASCO 2022

Immuncheckpoint-inhibitor therapy

Frank Griesinger, MD

SKYSCRAPER-02

ASCO 2022

No benefit for tiragolumab / novel anti-PD-1 mAB…

Sacha Rothschild, MD

SCLC: 100 seconds Multi Language

SKYSCRAPER-02

ASCO 2022

Le Tiragolumab n’apporte pas de bénéfice à la…

Denis Moro-Sibilot, MD

Prostate Cancer: Discussions

ENZAMET; ARASENS

ASCO 2022

mHSPC: Transatlantic differences in genetic testing &…

A. Merseburger, A. Morgans, E. Efstahiou, D. Murphy, N. Shore, A. Bjartell

TheraP; VISION

ASCO 2022

mCRPC: LuPSMA - new treatment option in mCRPC

M.-O. Grimm, D. Murphy, A. Bjartell, E. Efstathiou, G. Morgan, N. Shore

Propel; MAGNITUDE; BRCAAWAY

ASCO 2022

PARP inhibitors in mCRPC: Do we need more genetic…

M.-O. Grimm, A. Bjartell, E. Efstahiou, G. Morgan, N. Shore

Prostate Cancer: 100 seconds ENG

ENZAMET

ASCO 2022

The efficacy of doublets in mHSPC

Gil Morgan, MD

Vision

ASCO 2022

SUVmean is highly predictive of better PFS and OS

Declan Murphy, MD

VISION

ASCO 2022

Lu-PSMA effective regardless of prior or concomitant…

Axel Merseburger, MD

ENZAMET

ASCO 2022

ADT alone is no longer standard of care

Alicia Morgans, MD

ENZAMET

ASCO 2022

No big scoop, but encouraging results

Yohann Loriot, MD

TheraP

ASCO 2022

LuPSMA & cabazitaxel are better than SoC alone

Declan Murphy, MD

TheraP

ASCO 2022

Lu-PSMA in the third line

Axel Merseburger, MD

ASCO 2022

Ongoing trial invetiagting the impact of…

Neal Shore, MD

The highlights in GU cancers of ASCO22

ASCO 2022

The highlights in GU cancers of ASCO22

Ignacio Duran, MD

TheraP

ASCO 2022

TheraP shows no difference in overall survival between…

Gil Morgan, MD

TheraP

ASCO 2022

3 year overall survival of TheraP study

Anders Bjartell, MD

ASCO 2022

Phase 1 study on combining LuPSMA treatment with…

Anders Bjartell, MD

ASCO 2022

Surrogate endpoints in mHSPC

Anders Bjartell, MD

ASCO 2022

GGT impacts PCa patients care

Neal Shore, MD

BRCAAWAY

ASCO 2022

Arbiraterone + Olaparib: Is it synergistic?

Alicia Morgans, MD

ARASEC

ASCO 2022

Value of triple-therapy - complimentary study to…

Neal Shore, MD

VISION

ASCO 2022

SUV mean at PET images as a prognostic tool for PSMA…

Anders Bjartell, MD

ASCO 2022

PFS good surrogate endpoint for overall survival

Axel Merseburger, MD

ARAMIS

ASCO 2022

Frequent imaging for early detection of metastases in…

Marc-Oliver Grimm, MD

CHART

ASCO 2022

SHR3680 - do we need a new androgen receptor inhibitor

Axel Merseburger, MD

VISION

ASCO 2022

Further updates from the VISION trial

Alicia Morgans, MD

Prostate Cancer: 100 seconds Multi Language

TheraP

ASCO 2022

Treårs överlevnadsresultat i TheraP studien.

Anders Bjartell, MD

ASCO 2022

Tidigare endpoints I mHSPC studier

Anders Bjartell, MD

VISION

ASCO 2022

Kvantifiering av PMSA PET upptaget som prognostisk…

Anders Bjartell, MD

ASCO 2022

Pas de nouvelles sensationnelles mais des données…

Yohann Loriot, MD

ASCO 2022

Lo mas destacado en tumores GU en ASCO 2022

Ignacio Duran, MD

ASCO 2022

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…

Anders Bjartell, MD

Kidney Cancer: Discussion

CheckMate214

ASCO 2022

The relevance of quality of life in kidney cancer!

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

CheckMate9ER

ASCO 2022

What are the consequences for future trial design?

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

EVEREST

ASCO 2022

EVEREST: Inisghts from the negative trial

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

CLEAR Study; KEYNOTE-426; CheckMate (CM) 214; CheckMate 9ER

ASCO 2022

Combination Therapy is State of the Art in Metastatic…

Philipp Iavnyi, MD; Laura-Maria Krabbe, MD

Kidney Cancer: 100 seconds ENG

CheckMate 9ER; CheckMate 214

ASCO 2022

QoL & DepOR correlate with clinical outcomes - reminder…

Hans Hammers, MD

CheckMate 9ER

ASCO 2022

Depth of remission in firstline

Philipp Ivanyi, MD

LITESPARK-004

ASCO 2022

Belzutifann shows good tumor activity in renal cancer

Axel Merseburger, MD

EVEREST

ASCO 2022

Should Everolimus be revisited for high-risk patients?

Hans Hammers, MD

KEYNOTE-426

ASCO 2022

Combi Axi + Pembro also successful with good risk…

Axel Merseburger, MD

LITESPARK-004

ASCO 2022

Clear evidence for durable benefit for patients with…

Hans Hammers, MD

ASCO 2022

PSMA-PET may improve imaging of clear cell RCC

Hans Hammers, MD

ASCO 2022

Importance of health related quality of life

Philipp Ivanyi, MD

EVEREST

ASCO 2022

Should we be looking at Everolimus in the future?

Tom Powles, MD

The highlights in GU cancers of ASCO22

ASCO 2022

The highlights in GU cancers of ASCO22

Ignacio Duran, MD

Kidney Cancer: 100 seconds - Multi Language

ASCO 2022

Pas de nouvelles sensationnelles mais des données…

Yohann Loriot, MD

ASCO 2022

Lo mas destacado en tumores GU en ASCO 2022

Ignacio Duran, MD

Bladder Cancer: Discussions

COSMIC-021

ASCO 2022

New data on TKi utilization in bladder cancer

Laura-Maria Krabbe, MD; Marc-Oliver Grimm, MD

EV-103; RC-48

ASCO 2022

ADCs: do we enter a new era of therapy for urothelial…

L.-M. Krabbe, M.-O. Grimm, J. Bellmunt, Y. Loriot, T. Powles

AURA; SAKK 06/17; JAVELIN

ASCO 2022

The role of systemic treatment in the pre-operative…

L.-M. Krabbe, M.-O. Grimm, J. Bellmunt, Y. Loriot, T. Powles

Bladder Cancer: 100 seconds ENG

ENZAMET

ASCO 2022

No big scoop, but encouraging results

Yohann Loriot, MD

EV-301; RC48-ADC

ASCO 2022

Exciting future for ADCs

Tom Powles, MD

ASCO 2022

Maintenance concepts

Philipp Ivanyi, MD

ASCO 2022

ADCs: News from ASCO 2022

Philipp Ivanyi, MD; Peter Goebell, MD

COSMIC-021; ATLANTIS

ASCO 2022

The end of of VEGF-targeted therapy in urothelial…

Tom Powles, MD

ATLANTIS; MAIN_CAV

ASCO 2022

My highlights of metastasized urothelial cancer

Petros Grivas, MD

ASCO 2022

BCG failure

Philipp Ivanyi, MD

QUILT 3.032; SWOG S1314

ASCO 2022

My highlights in localized urothelial cancer

Petros Grivas, MD

The highlights in GU cancers of ASCO22

ASCO 2022

The highlights in GU cancers of ASCO22

Ignacio Duran, MD

SAKK 06/17

ASCO 2022

Perioperative immuno-chemotherapy in MIBC

Laura-Maria Krabbe, MD

CREST cohort B

ASCO 2022

Investigating sasanlimab in BCG-unresponsive NMIBC

Neal Shore, MD

Bladder Cancer: 100 seconds - Multi Language

ASCO 2022

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το…

Petros Grivas, MD

ASCO 2022

Lo mas destacado en tumores GU en ASCO 2022

Ignacio Duran, MD

Varia

ASCO 2022

News from Sarcoma

Philipp Ivanyi, MD

ASCO 2022

Precision oncology - NTRK worth to search the patients

Philipp Ivanyi, MD

ASCO 2022

Few testicular tumors after 5 years

Axel Merseburger, MD

ASCO22

Opportunities & challenges of cancer genetics

C. Moisidis-Tesch, MD; L.P. Shulman, MD

ASCO 2022

Radiotherapy as a new standard for cisplatin ineligible…

Philipp Ivanyi, MD

ASCO 2022

Systemic therapy

Philipp Ivanyi